A study comparing the use of bevacizumab (marketed as Avastin) and ranibizumab (marketed as Lucentis) has shown that the two “wet” AMD treatments are equally effective at halting vision loss. The study, conducted by Dr. Donald S. Fong of the Kaiser Permanente Southern California